Ian Flinn, MD
Hematology & Oncology · Nashville, TNNPI 1417990367
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $81,435 of the $94,358 with a category attached, or 86.3%. 53 manufacturers reported payments, led by Gilead at 27.3% of the total. Reporting peaked in 2019 at $26,239 and has fallen 65.4% since, to $9,068 in 2025.
Across 374 payments — averaging $252.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$26K
- AbbVie$21K
- Beigene USA, Inc.$10K
- Genentech, Inc.$9K
- F. Hoffmann-la Roche AG$5K
- Sanofi$5K
- plus $19K from 47 others
Across 4,030 payments — averaging $10,205 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Beigene, Ltd.$11.3M
- Seagen Inc.$5.4M
- AstraZeneca$5.2M
- Genentech, Inc.$4.5M
- Gilead$2.2M
- Novartis$1.9M
- plus $10.7M from 30 others
What the payments were for
- Consulting fees$81,43586%
- Speaking & faculty fees$3,8494%
- Travel & lodging$7021%
- Food & beverage$8,3459%
- Education$280%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$94,358 in reported general payments places this provider in the 85th percentile of 251 hematology & oncology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CalquenceAcalabrutinib Maleate | 134 | $1,921,259 |
| BrukinsaZanubrutinib | 116 | $1,623,396 |
| VenclextaVenetoclax | 94 | $972,781 |
| ImbruvicaIbrutinib | 56 | $918,186 |
| JaypircaPirtobrutinib | 29 | $606,399 |
| PomalystPomalidomide | 26 | $546,517 |
| TasignaNilotinib Hcl | 13 | $254,906 |
| RevlimidLenalidomide | 15 | $243,948 |
| JakafiRuxolitinib Phosphate | 11 | $133,664 |
| SprycelDasatinib | 11 | $111,926 |
| EliquisApixaban | 13 | $12,058 |
| Acyclovir | 122 | $2,142 |
| Dexamethasone | 28 | $550 |
| ValacyclovirValacyclovir Hcl | 16 | $477 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 49 | $285 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence | $372 | $1,921,259134 claims |
| Beigene USA, Inc.Brukinsa | $9,646 | $1,623,396116 claims |
| AbbVieVenclexta | $20,703 | $972,78194 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $175 | $918,18656 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel | $126 | $658,44337 claims |
| Lilly USA, LLCJaypirca | $191 | $606,39929 claims |
| NovartisTasigna | $552 | $254,90613 claims |
| Bristol Myers SquibbRevlimid | $264 | $243,94815 claims |
| Incyte CorporationJakafi | $205 | $133,66411 claims |
| PfizerEliquis | $151 | $12,05813 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $157 | $2,142122 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 251 hematology & oncology providers in Tennessee.
Other hematology & oncology in Nashville
- Jonathan AbbasNashville$1.3M
- Alan TanNashville$1.1M
- Kent ShihNashville$900K
- Brian RiniNashville$601K
- Wade IamsNashville$601K
- Krish PatelNashville$531K
- Sandeep RajanNashville$465K
- Todd BauerNashville$357K
- Muhamed BaljevicNashville$313K
- Olalekan OluwoleNashville$311K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.